Impact of insulin pumps on glycaemic control in a pump-naïve paediatric regional population. 2012

Martin de Bock, and Alistair Jan Gunn, and Jean-Ann Holt, and José G B Derraik, and Peter Reed, and Wayne Cutfield, and Fran Mouat, and Paul Hofman, and Craig Jefferies
The Liggins Institute Department of Physiology, University of Auckland, Auckland, New Zealand. m.debock@auckland.ac.nz

OBJECTIVE To examine the clinical impact of insulin-pump therapy for children with type 1 diabetes mellitus (T1DM) in a regional paediatric service, Auckland, New Zealand. METHODS Retrospective analysis of children with T1DM from the Starship paediatric diabetes database who started on insulin-pump therapy from 2002 to 2008 compared with the whole T1DM population and with an equal number of non-pump patients matched by age, sex, ethnicity and duration of diabetes. RESULTS From 621 subjects with 6680 clinic visits, 75 children were treated with insulin-pump therapy for more than 12 months. Transitioning to insulin-pump treatment was associated with an improvement in HbA1c compared with baseline (-0.3%/year, P < 0.001) for up to 3 years. In contrast, despite similar deprivation scores, non-pump controls showed a continuing trend to higher HbA1C values (+0.2%/year, P < 0.01). The risk of severe hypoglycaemia fell after pump start (from 27 (0-223) to 5 (0-0.91) events/100 patient years) with no change in non-pump controls; the rate of diabetic ketoacidosis remained low in both groups. CONCLUSIONS In a pump-naïve regional paediatric population, insulin-pump therapy for T1DM was safe and effective, and associated with sustained improvements in HbA1c and lower risk of hypoglycaemia.

UI MeSH Term Description Entries
D007003 Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH. Fasting Hypoglycemia,Postabsorptive Hypoglycemia,Postprandial Hypoglycemia,Reactive Hypoglycemia,Hypoglycemia, Fasting,Hypoglycemia, Postabsorptive,Hypoglycemia, Postprandial,Hypoglycemia, Reactive
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007332 Insulin Infusion Systems Portable or implantable devices for infusion of insulin. Includes open-loop systems which may be patient-operated or controlled by a pre-set program and are designed for constant delivery of small quantities of insulin, increased during food ingestion, and closed-loop systems which deliver quantities of insulin automatically based on an electronic glucose sensor. Pancreas, Artificial Endocrine,Programmable Implantable Insulin Pump,beta Cell, Artificial,Implantable Programmable Insulin Pump,Insulin Pump, Programmable Implantable,Pump, Programmable Implantable Insulin,Artificial Endocrine Pancreas,Artificial beta Cell,Artificial beta Cells,Cell, Artificial beta,Cells, Artificial beta,Endocrine Pancreas, Artificial,Infusion System, Insulin,Infusion Systems, Insulin,Insulin Infusion System,System, Insulin Infusion,Systems, Insulin Infusion,beta Cells, Artificial
D008297 Male Males
D009520 New Zealand A group of islands in the southwest Pacific. Its capital is Wellington. It was discovered by the Dutch explorer Abel Tasman in 1642 and circumnavigated by Cook in 1769. Colonized in 1840 by the New Zealand Company, it became a British crown colony in 1840 until 1907 when colonial status was terminated. New Zealand is a partly anglicized form of the original Dutch name Nieuw Zeeland, new sea land, possibly with reference to the Dutch province of Zeeland. (From Webster's New Geographical Dictionary, 1988, p842 & Room, Brewer's Dictionary of Names, 1992, p378)
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus

Related Publications

Martin de Bock, and Alistair Jan Gunn, and Jean-Ann Holt, and José G B Derraik, and Peter Reed, and Wayne Cutfield, and Fran Mouat, and Paul Hofman, and Craig Jefferies
October 2010, Diabetic medicine : a journal of the British Diabetic Association,
Martin de Bock, and Alistair Jan Gunn, and Jean-Ann Holt, and José G B Derraik, and Peter Reed, and Wayne Cutfield, and Fran Mouat, and Paul Hofman, and Craig Jefferies
October 2016, Diabetic medicine : a journal of the British Diabetic Association,
Martin de Bock, and Alistair Jan Gunn, and Jean-Ann Holt, and José G B Derraik, and Peter Reed, and Wayne Cutfield, and Fran Mouat, and Paul Hofman, and Craig Jefferies
February 2017, British journal of community nursing,
Martin de Bock, and Alistair Jan Gunn, and Jean-Ann Holt, and José G B Derraik, and Peter Reed, and Wayne Cutfield, and Fran Mouat, and Paul Hofman, and Craig Jefferies
April 2009, Lancet (London, England),
Martin de Bock, and Alistair Jan Gunn, and Jean-Ann Holt, and José G B Derraik, and Peter Reed, and Wayne Cutfield, and Fran Mouat, and Paul Hofman, and Craig Jefferies
April 2009, Lancet (London, England),
Martin de Bock, and Alistair Jan Gunn, and Jean-Ann Holt, and José G B Derraik, and Peter Reed, and Wayne Cutfield, and Fran Mouat, and Paul Hofman, and Craig Jefferies
April 2009, Lancet (London, England),
Martin de Bock, and Alistair Jan Gunn, and Jean-Ann Holt, and José G B Derraik, and Peter Reed, and Wayne Cutfield, and Fran Mouat, and Paul Hofman, and Craig Jefferies
June 2003, Nursing,
Martin de Bock, and Alistair Jan Gunn, and Jean-Ann Holt, and José G B Derraik, and Peter Reed, and Wayne Cutfield, and Fran Mouat, and Paul Hofman, and Craig Jefferies
December 1995, Diabete & metabolisme,
Martin de Bock, and Alistair Jan Gunn, and Jean-Ann Holt, and José G B Derraik, and Peter Reed, and Wayne Cutfield, and Fran Mouat, and Paul Hofman, and Craig Jefferies
September 2009, The Medical journal of Australia,
Martin de Bock, and Alistair Jan Gunn, and Jean-Ann Holt, and José G B Derraik, and Peter Reed, and Wayne Cutfield, and Fran Mouat, and Paul Hofman, and Craig Jefferies
January 2010, The Medical journal of Australia,
Copied contents to your clipboard!